Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals (Nasdaq: XENE) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 18 at 9:10 a.m. ET and the Jefferies London Healthcare Conference 2024 on November 20 at 1:30 PM GMT / 8:30 am ET.
Xenon is a neuroscience-focused biopharmaceutical company developing ion channel products for epilepsy and depression. Their lead product, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple indications. Webcasts of the presentations will be available on Xenon's website investor section.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato la sua partecipazione a due prossime conferenze per investitori nel novembre 2024. L'azienda presenterà alla Stifel 2024 Healthcare Conference il 18 novembre alle 9:10 ora ET e alla Jefferies London Healthcare Conference 2024 il 20 novembre alle 13:30 GMT / 8:30 ora ET.
Xenon è un'azienda biofarmaceutica focalizzata sulle neuroscienze che sviluppa prodotti a base di canali ionici per l'epilessia e la depressione. Il loro prodotto di punta, azetukalner, è un apritore del canale potassico Kv7 attualmente in fase avanzata di sviluppo clinico per molteplici indicazioni. Le registrazioni delle presentazioni saranno disponibili nella sezione investitori del sito web di Xenon.
Xenon Pharmaceuticals (Nasdaq: XENE) ha anunciado su participación en dos próximas conferencias para inversores en noviembre de 2024. La empresa presentará en la Stifel 2024 Healthcare Conference el 18 de noviembre a las 9:10 a.m. ET y en la Jefferies London Healthcare Conference 2024 el 20 de noviembre a la 1:30 p.m. GMT / 8:30 a.m. ET.
Xenon es una empresa biofarmacéutica centrada en neurociencias que desarrolla productos de canales iónicos para la epilepsia y la depresión. Su producto principal, azetukalner, es un abridor del canal de potasio Kv7 que se encuentra en una fase avanzada de desarrollo clínico para múltiples indicaciones. Las transmisiones de las presentaciones estarán disponibles en la sección de inversores del sitio web de Xenon.
젠온 제약 (Nasdaq: XENE)는 2024년 11월에 예정된 두 개의 투자자 회의에 참가한다고 발표했습니다. 회사는 11월 18일 오전 9시 10분 ET에 Stifel 2024 Healthcare Conference에서, 11월 20일 오후 1시 30분 GMT / 오전 8시 30분 ET에 Jefferies London Healthcare Conference 2024에서 발표할 예정입니다.
젠온은 간질 및 우울증을 위한 이온 채널 제품을 개발하는 신경과학 중심의 생명공학 회사입니다. 그들의 주력 제품인 아제투칼너는 다수의 적응증에 대해 후기 단계의 임상 개발 중인 Kv7 칼륨 채널 개방제입니다. 발표 내용은 젠온의 웹사이트 투자자 섹션에서 확인할 수 있습니다.
Xenon Pharmaceuticals (Nasdaq: XENE) a annoncé sa participation à deux conférences pour investisseurs à venir en novembre 2024. L'entreprise présentera à la Stifel 2024 Healthcare Conference le 18 novembre à 9h10 ET et à la Jefferies London Healthcare Conference 2024 le 20 novembre à 13h30 GMT / 8h30 ET.
Xenon est une entreprise biopharmaceutique axée sur les neurosciences qui développe des produits à base de canaux ioniques pour l'épilepsie et la dépression. Leur produit phare, azetukalner, est un ouvreur de canal potassique Kv7 en phase avancée de développement clinique pour plusieurs indications. Les retransmissions des présentations seront disponibles dans la section investisseurs du site web de Xenon.
Xenon Pharmaceuticals (Nasdaq: XENE) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im November 2024 angekündigt. Das Unternehmen wird am 18. November um 9:10 Uhr ET auf der Stifel 2024 Healthcare Conference und am 20. November um 13:30 GMT / 8:30 Uhr ET auf der Jefferies London Healthcare Conference 2024 präsentieren.
Xenon ist ein biopharmazeutisches Unternehmen, das sich auf Neurowissenschaften konzentriert und Ionenkanalprodukte für Epilepsie und Depressionen entwickelt. Ihr Hauptprodukt, azetukalner, ist ein Kv7-Kaliumkanalöffner, der sich in der späten klinischen Entwicklungsphase für mehrere Indikationen befindet. Mitschnitte der Präsentationen werden im Investorenbereich der Xenon-Website verfügbar sein.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences.
- Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 9:10 a.m. ET (webcast link)
- Jefferies London Healthcare Conference 2024 on Wednesday, November 20, 2024 at 1:30 PM GMT / 8:30 am ET (webcast link)
Details about company presentations, webcasts, and other events can be found on the “Investors” section of Xenon's website. When available, webcasts will be posted for replay following the event. The above-listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals (XENE) present at the Stifel Healthcare Conference 2024?
What is Xenon Pharmaceuticals' (XENE) main product in development?
Which therapeutic areas does Xenon Pharmaceuticals (XENE) focus on?
When is Xenon's (XENE) presentation at the Jefferies London Healthcare Conference 2024?
